You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Titer

Showing 1 - 25 of 3,610
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Hemophilia A With Inhibitor Trial (SCT800 and Daratumumab)

Not yet recruiting
  • Hemophilia A With Inhibitor
  • SCT800 and Daratumumab
  • (no location specified)
May 24, 2023

Hemorrhagic Shock, Acute Blood Loss Anemia, Traumatic Brain Injury Trial in Loma Linda (Routine labs)

Recruiting
  • Hemorrhagic Shock
  • +2 more
  • Routine labs
  • Loma Linda, California
    Loma Linda University Health
Aug 9, 2022

COVID-19 Trial in Milwaukee (anti-SARS-CoV-2 convalescent plasma)

Completed
  • COVID-19
  • anti-SARS-CoV-2 convalescent plasma
  • Milwaukee, Wisconsin
    Froedtert Hospital
Aug 23, 2022

Hemorrhagic Shock, Trauma Injury Trial (Low Titer Group O Whole Blood (LTOWB), Placebo, Tranexamic Acid (TXA))

Not yet recruiting
  • Hemorrhagic Shock
  • Trauma Injury
  • Low Titer Group O Whole Blood (LTOWB)
  • +3 more
  • (no location specified)
Oct 9, 2023

Status Epilepticus Trial in Chengdu (Perform autoimmune encephalitis titer tests)

Completed
  • Status Epilepticus
  • Perform autoimmune encephalitis titer tests
  • Chengdu, Sichuan, China
    Jie Liu
Dec 13, 2022

Wounds and Injuries, Shock, Hemorrhagic Trial in United States (LTOWB, Components)

Not yet recruiting
  • Wounds and Injuries
  • Shock, Hemorrhagic
  • LTOWB
  • Components
  • Birmingham, Alabama
  • +11 more
Jan 20, 2023

COVID-19 Trial in Chapel Hill (High-titer Convalescent COVID-19 Plasma (CCP1), Standard-titer Convalescent COVID-19 plasma

Completed
Has Results
  • COVID-19
  • High-titer Convalescent COVID-19 Plasma (CCP1)
  • Standard-titer Convalescent COVID-19 plasma (CCP2)
  • Chapel Hill, North Carolina
    University of North Carolina Health Care
Dec 1, 2021

Anti-SARS-CoV-2 IgG ANTibodiEs After Vaccination Study in

Recruiting
  • SARS-CoV2 Infection
  • SARS-CoV2 Antibodies
  • assessment of the anti-SARS-CoV-2 IgG antibody titer in 3-dose schedule
  • assessment of the anti-SARS-CoV-2 IgG antibody titer in 2-dose schedule
  • Bydgoszcz, Poland
    Department of Transplantology and General Surgery, Dr. A. Jurasz
Dec 15, 2021

Rabies Human, Antibody Titer Trial in Changchun (rabies vaccine)

Recruiting
  • Rabies Human
  • Antibody Titer
  • rabies vaccine
  • Changchun, Jilin, China
    Changchun Zhuoyi Biological Co., Ltd
Sep 18, 2022

Hemorrhagic Shock, Traumatic Injury Trial in Pittsburgh (low titer whole blood, Standard Care)

Recruiting
  • Hemorrhagic Shock
  • Traumatic Injury
  • low titer whole blood
  • Standard Care
  • Pittsburgh, Pennsylvania
    University of Pittsburgh
Apr 19, 2022

Anti-SARS-CoV-2 IgG ANTibodiEs After Vaccination Study

Active, not recruiting
  • SARS-CoV2 Infection
  • SARS-CoV2 Antibodies
  • assessment of the anti-SARS-CoV-2 IgG antibody titer in 3-dose schedule
  • assessment of the anti-SARS-CoV-2 IgG antibody titer in 2-dose schedule
  • Bydgoszcz, Kujawsko-Pomorskie, Poland
    Cardiology Department, Dr. A. Jurasz University Hospital
Nov 4, 2021

Vaccine Adverse Reaction, Seroconversion Trial in Zagazig (SARS-Cov-2 neutralizing antibody titer)

Completed
  • Vaccine Adverse Reaction
  • Seroconversion
  • SARS-Cov-2 neutralizing antibody titer
  • Zagazig, Sharkia, Egypt
    Zagazig University Faculty of Medicine
Feb 7, 2022

COVID, Infectious Disease Trial in Boston (High-Titer COVID-19 Convalescent Plasma (HT-CCP), Standard Plasma (FFP))

Terminated
  • COVID
  • Infectious Disease
  • High-Titer COVID-19 Convalescent Plasma (HT-CCP)
  • Standard Plasma (FFP)
  • Boston, Massachusetts
    Brigham and Women's Hospital
Aug 9, 2021

Isotype Switching and Neutralizing Capacity to COVID-19 Variants

Active, not recruiting
  • COVID-19
    • Beijing, China
      Center for Disease Control and Prevention
    Oct 19, 2021

    COVID Trial in Stony Brook (Convalescent Plasma, Standard Donor Plasma)

    Terminated
    Has Results
    • COVID
    • Convalescent Plasma
    • Standard Donor Plasma
    • Stony Brook, New York
      Stony Brook University Hospital
    Dec 2, 2021

    Dengue Trial in Mexico city (Estimate the distribution of antibodies by serotype by Dengue virus in areas of low and high

    Not yet recruiting
    • Dengue
    • Estimate the distribution of antibodies by serotype by Dengue virus in areas of low and high incidence of dengue
    • Mexico city, Mexico
      Mexican Society of Public Health
    Mar 2, 2022

    Drawn From Central Venous Lines and Venipuncture

    Terminated
    • Hemophilia A
    • +4 more
    • Peripheral Vein Blood draw
    • Kansas City, Missouri
      Children's Mercy Hospital
    Jan 5, 2021

    Hemophilia A or B With Inhibitors, Hemophilia A, Hemophilia B Trial in Worldwide (Factor VIII Inhibitor Bypassing Activity

    Completed
    Has Results
    • Hemophilia A or B With Inhibitors
    • +2 more
    • Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated)
    • Chicago, Illinois
    • +16 more
    Apr 29, 2021

    Hemophilia A With Inhibitor, Hemophilia A Without Inhibitor Trial in Seoul (Emicizumab subcutaneous injection)

    Recruiting
    • Hemophilia A With Inhibitor
    • Hemophilia A Without Inhibitor
    • Emicizumab subcutaneous injection
    • Seoul, Korea, Republic of
      Yonsei University Severance Hospital
    Jul 15, 2021

    Cancer, Breast Cancer, Gastric Cancer Trial in Bron, Lyon, Pierre-Bénite (Blood draws)

    Recruiting
    • Cancer
    • +16 more
    • Blood draws
    • Bron, France
    • +16 more
    Jul 12, 2021

    Shock, Septic, Sepsis, Hypoglobulinemia Trial in Modena (IgM-enriched polyclonal immunoglobulins titer-based treatment,

    Recruiting
    • Shock, Septic
    • +2 more
    • IgM-enriched polyclonal immunoglobulins titer-based treatment
    • IgM-enriched polyclonal immunoglobulins Flat treatment
    • Modena, Italy
      ICU- University Hospital Modena
    May 3, 2021

    Rituximab-Induced Hypogammaglobulinemia in Multiple Sclerosis

    Unknown status
    • Multiple Sclerosis
    • Hypogammaglobulinemia
    • Serum immunoglobulin titer
    • Sari, Iran, Islamic Republic of
      Bu Ali Sina hospital
    Jul 8, 2020

    Pneumonia, Interstitial Trial (high-titer anti-Sars-CoV-2 plasma, oxygen therapy)

    Unknown status
    • Pneumonia, Interstitial
    • high-titer anti-Sars-CoV-2 plasma
    • oxygen therapy
    • (no location specified)
    Apr 2, 2020

    Coronavirus Trial (Convalescent Plasma)

    Withdrawn
    • Coronavirus
    • Convalescent Plasma
    • (no location specified)
    Apr 6, 2020

    Nutrient; Excess, Product Use Issue Trial in Perugia (Revifast, pure resveratrol)

    Completed
    • Nutrient; Excess
    • Product Use Issue
    • Revifast
    • pure resveratrol
    • Perugia, PG, Italy
      Deparment of Chemistry, Biology and Biotechnology
    Apr 22, 2020